Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University Experience

This publication has 11 references indexed in Scilit:

• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2003
• Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer*
  Chest, 2003
• Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
  British Journal of Cancer, 2002
• ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
  Journal of Clinical Oncology, 2002
• Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2002
• Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
  Journal of Clinical Oncology, 2002
• The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
  The Oncologist, 2001
• Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 2000
• A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
  Lung Cancer, 2000
• Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1999